{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=3", "query": { "intervention": "Arm 1- Dose Escalation", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T05:27:45.433Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02440685", "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Lymphoma, Follicular", "Cancer", "Neoplasm", "Tumor", "Lymphoma, Malignant", "Lymphoma, B-cell", "Lymphoma, Non-Hodgkin", "B-Cell Chronic Lymphocytic Leukemia", "B-Cell Leukemia, Chronic", "B-Lymphocytic Leukemia, Chronic", "Chronic Lymphocytic Leukemia", "Leukemia, Lymphocytic, Chronic", "Leukemia, Lymphocytic, Chronic, B Cell", "Myelofibrosis", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "Lymphoma, T Cell, Peripheral", "Peripheral T-Cell Lymphoma", "T-Cell Lymphoma, Peripheral" ], "interventions": [ { "name": "ASN002 Dose Escalation", "type": "DRUG" }, { "name": "ASN002 RD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-05", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 12, "location_summary": "Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02440685" }, { "nct_id": "NCT01082068", "title": "Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "XL147 (SAR245408)", "type": "DRUG" }, { "name": "XL765 (SAR245409)", "type": "DRUG" }, { "name": "letrozole (Femara)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 72, "start_date": "2010-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 11, "location_summary": "Los Angeles, California • Denver, Colorado • Fort Meyers, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082068" }, { "nct_id": "NCT06220201", "title": "A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis", "Myasthenia Gravis" ], "interventions": [ { "name": "CC-97540", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 120, "start_date": "2024-03-28", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "North Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06220201" }, { "nct_id": "NCT03414736", "title": "A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "SAR425899", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2018-01-19", "completion_date": "2018-10-05", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 3, "location_summary": "Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas", "locations": [ { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414736" }, { "nct_id": "NCT06233110", "title": "Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stefanie Sarantopoulos, MD, PhD.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2025-10-29", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06233110" }, { "nct_id": "NCT02538627", "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "MM-151", "type": "DRUG" }, { "name": "MM-121", "type": "DRUG" }, { "name": "MM-141", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-08", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 5, "location_summary": "Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538627" }, { "nct_id": "NCT06046820", "title": "The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency", "Autosomal Recessive Hypophosphatemic Rickets", "Generalized Arterial Calcification of Infancy" ], "interventions": [ { "name": "INZ-701", "type": "DRUG" }, { "name": "Control Arm (Conventional Therapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inozyme Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "12 Years", "sex": "ALL", "summary": "1 Year to 12 Years" }, "enrollment_count": 27, "start_date": "2023-11-05", "completion_date": "2026-08-19", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 3, "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania • Fort Worth, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06046820" }, { "nct_id": "NCT05533697", "title": "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "mRNA-4359", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 361, "start_date": "2022-09-01", "completion_date": "2032-02-18", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 16, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05533697" }, { "nct_id": "NCT04065399", "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Mixed Lineage Acute Leukemia", "Mixed Phenotype Acute Leukemia", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "revumenib", "type": "DRUG" }, { "name": "cobicistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": null, "sex": "ALL", "summary": "30 Days and older" }, "enrollment_count": 447, "start_date": "2019-11-05", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 22, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 17 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04065399" }, { "nct_id": "NCT03111992", "title": "Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "PDR001", "type": "DRUG" }, { "name": "CJM112", "type": "DRUG" }, { "name": "LCL161", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-12-18", "completion_date": "2020-03-02", "has_results": false, "last_update_posted_date": "2022-02-09", "last_synced_at": "2026-11-15T05:27:45.433Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Nashville, Tennessee", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03111992" } ] }